Современные взгляды на обогащение рациона детского и взрослого населения витамином D: проблемы и перспективы
Современные взгляды на обогащение рациона детского и взрослого населения витамином D: проблемы и перспективы
Плудовский П., Захарова И.Н., Климов Л.Я. Современные взгляды на обогащение рациона детского и взрослого населения витамином D: проблемы и перспективы. Педиатрия (Прил. к журн. Consilium Medicum). 2017; 3: 10–17.
________________________________________________
Pludowski P., Zakharova I.N., Klimov L.Ya. Modern views on enriching the diet of children and adults with vitamin D: problems and prospects. Pediatrics (Suppl. Consilium Medicum). 2017; 3: 10–17.
Современные взгляды на обогащение рациона детского и взрослого населения витамином D: проблемы и перспективы
Плудовский П., Захарова И.Н., Климов Л.Я. Современные взгляды на обогащение рациона детского и взрослого населения витамином D: проблемы и перспективы. Педиатрия (Прил. к журн. Consilium Medicum). 2017; 3: 10–17.
________________________________________________
Pludowski P., Zakharova I.N., Klimov L.Ya. Modern views on enriching the diet of children and adults with vitamin D: problems and prospects. Pediatrics (Suppl. Consilium Medicum). 2017; 3: 10–17.
В статье представлены данные литературы о метаболизме и биологической роли витамина D в организме, сфокусировано внимание на некальциемических плейотропных эффектах, а также механизмах его влияния на иммунную, эндокринную, сердечно-сосудистую, нервную системы. Представлены современные взгляды на оптимальный уровень, критерии дефицита и гипервитаминоза D. Показана необходимость поддержания достаточного уровня активных метаболитов для обеспечения пролонгированных эффектов на состояние здоровья в детском и взрослом возрасте, причем некальциемические эффекты достигаются при более высоком уровне активных метаболитов витамина D. Достижение нормальной обеспеченности витамином D практически невозможно без обогащения рациона с помощью содержащих витамин D продуктов и/или приема препаратов холекальциферола. Представлены современные рекомендации по лечебным дозировкам витамина D, использующимся при лабораторно подтвержденном дефиците. Представлены сведения о высокой безопасности терапевтических дозировок витамина D, которые позволяют считать D-витаминизацию рационов детского и взрослого населения одной из задач системы здравоохранения в рамках концепции профилактики наиболее распространенных социально значимых заболеваний.
The article presents literature data on the metabolism and biological role of vitamin D in the body, focused attention on noncalcemic pleiotropic effects, as well as the mechanisms of its influence on the immune, endocrine, cardiovascular, nervous systems. Presented views on the optimal level, criteria for deficiency and hypervitaminosis D. The need to maintain a sufficient level of active metabolites to ensure prolonged effects on health in childhood and adulthood, and noncalcemic effects are achieved with a higher level of active metabolites of vitamin D. Achieving normal supply of vitamin D is practically impossible without enriching the diet with vitamin D-containing products and / or taking medications with choleric alciferol. Presented are current recommendations on therapeutic dosages of vitamin D, used in laboratory-confirmed deficits. Data on high safety of therapeutic dosages of vitamin D are given, which allow to consider D-vitaminization of rations for children and adults as one of the tasks of the health care system within the framework of the concept of prevention of the most common socially significant diseases.
Key words: vitamin D, calcicemic effects, pleiotropic effect, criteria of availability, prevention, therapeutic doses, enrichment of the diet, children, adults.
1. https://www.ncbi.nlm.nih.gov/pubmed/?term=vitamin+D on 16.10.2016.
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=vitamin+D+and+pleiotropic on 16.10.2016.
3. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014; 2 (1): 76–89.
4. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2 (4): 307–20.
5. Garland CF, Kim JJ, Mohr SB et al. Meta-analysis of AllCause Mortality According to Serum 25-Hydroxyvitamin D. Am J Public Health 2014; 104 (8): E43–E50.
6. Hossein-Nezhad A, Holick MF. Vitamin D for Health: A Global Perspective. Mayo Clin Proc 2013; 88 (7): 720–55.
7. Pludowski P, Holick MF, Pilz S et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, de- mentia and mortality – A review of recent evidence. Autoimmun Rev 2013; 12 (10): 976–89.
8. Song Y, Wang L, Pittas AG et al. Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes. Diabetes Care 2013; 36 (5): 1422–8.
9. Souberbielle JC, Body JJ, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 9 (11): 709–15.
10. Wang L, Song Y, Manson JE et al. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease A Meta-Analysis of Prospective Studies. Cir Cardiovasc Qual
om 2012; 5 (6): 819–29.
11. https://www.vitamindcouncil.org/health-conditions on 16.10.2016.
12. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 2014; 72 (1): 48–54.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911–30.
14. Holick MF. Evolution and function of vitamin D. 2003.
15. Holick MF. Vitamin D: A millenium perspective. J Cell Biochem 2003.
16. Белая Ж.Е., Рожинская Л.Я. Витамин D в терапии остеопороза: его роль в комбинации с препаратами для лечения остеопороза, внескелетные эффекты. Эффективная фармакотер. 2013 (38): 14–29. / Belaia Zh.E., Rozhinskaia L.Ia. Vitamin D v terapii osteoporoza: ego rol' v kombinatsii s preparatami dlia lecheniia osteoporoza, vneskeletnye effekty. Effektivnaia farmakoter. 2013 (38): 14–29. [in Russian]
17. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357; (3): 266–81.
18. Новиков П.В. Рахит и наследственные рахитоподобные заболевания у детей. М.: Триада-Х, 2006. / Novikov P.V. Rakhit i nasledstvennye rakhitopodobnye zabolevaniia u detei. M.: Triada-Kh, 2006. [in Russian]
19. Захарова И.Н., Яблочкова С.В., Дмитриева Ю.А. Известные и неизвестные эффекты витамина D. Вопр. соврем. педиатрии. 2013; 12 (2): 20–5. / Zakharova I.N., Iablochkova S.V., Dmitrieva Iu.A. Izvestnye i neizvestnye effekty vitamina D. Vopr. sovrem. pediatrii. 2013; 12 (2): 20–5. [in Russian]
20. Захарова И.Н., Коровина Н.А., Боровик Т.Э., Дмитриева Ю.А. Рахит и гиповитаминоз D – новый взгляд на давно существующую проблему. Пособие для врачей. М., 2011. / Zakharova I.N., Korovina N.A., Borovik T.E., Dmitrieva Iu.A. Rakhit i
gipovitaminoz D – novyi vzgliad na davno sushchestvuiushchuiu problemu. Posobie
dlia vrachei. M., 2011. [in Russian]
21. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin
D. Trends Biochem Sci 2004; 29 (12): 664–73.
22. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action,
and clinical applications. Primer on the Metabolic Bone diseases and disorders of Mineral Metabolism ed. by M.J.Favus. 6th edition. Chapter 17. Washington, dc: American society for Bone and Mineral Research, 2006; р. 129–37.
23. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine
system essential for good health. Am J Clin Nutr 2008; 88 (2): 491–9.
24. De Borst MH, de Boer RA, Stolk RP et al. Vitamin D deficiency: universal risk factor for multifactorial diseases? Curr Drug Targets 2011; 12 (1): 97–106.
25. Ramagopalan SV, Heger A, Berlanga AJ et al. A ChIP-seq-defined genome-wide map
of vitamin D receptor binding: аssociations with disease and evolution. Genome Res 2010; 20 (10): 1352–60.
26. Торшин И.Ю., Громова О.А. Экспертный анализ данных в молекулярной фармакологии. М.: МЦНМО, 2012. / Torshin I.Iu., Gromova O.A. Ekspertnyi analiz dannykh v molekuliarnoi farmakologii. M.: MTsNMO, 2012. [in Russian]
27. Mikirova NA, Belcaro G, Jackson JA, Riordan NH. Vitamin D concentrations, endothelial progenitor cells, and cardiovascular risk factors. Pan Minerva Med. 2010; 52 (2 Suppl. 1): 81–7.
28. Pilz S, Tomaschitz A. Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther 2010; 8 (11): 1599–608.
29. Annweiler C, Dursun E, Feron F et al. “Vitamin D and cognition in older adults”: updated international recommendations. J Intern Med 2015; 277 (1): 45–57.
30. Мальцев С.В., Мансурова Г.Ш. Метаболизм витамина D и пути реализации его
основных функций. Практическая мед. 2014; 9 (85): 12–8. / Mal'tsev S.V., Mansurova
G.Sh. Metabolizm vitamina D i puti realizatsii ego osnovnykh funktsii. Prakticheskaia
med. 2014; 9 (85): 12–8. [in Russian]
31. Hoenderop JG, Nilius B, Bindels RJ. Calcium Absorption Across Epithelia. Physiol Rev 2005; 85 (1): 373–422.
32. Hoenderop JG, van der Kemp AW, Hartog A et al. Molecular identification of the
apical Ca2+ channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J Biol Chem 1999; 274 (13): 8375–8.
33. Dardenne O, Prud’homme J, Arabian A et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142 (7): 3135–41.
34. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the vitamin D receptor exhibit
impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997; 16 (4): 391–6.
35. Ершова О.Б., Белова К.Ю., Назарова А.В. Кальций и витамин D: все ли мы о них
знаем? Рус. мед. журн. 2011; 19 (12): 719–24. / Ershova O.B., Belova K.Iu., Nazarova
A.V. Kal'tsii i vitamin D: vse li my o nikh znaem? Rus. med. zhurn. 2011; 19 (12): 719–24. [in Russian]
36. Van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004; 10 (21): 2535–55.
37. Зоткин Е.Г., Шварц Г.Я. Возможности клинического применения витамина D и
его активных метаболитов. Эффективная фармакотер. 2013; 38: 50–9. / Zotkin E.G., Shvarts G.Ia. Vozmozhnosti klinicheskogo primeneniia vitamina D i ego aktivnykh metabolitov. Effektivnaia farmakoter. 2013; 38: 50–9. [in Russian]
38. Пинелис В.Г., Тихомиров Е.Е., Щеплягина Л.А., Баранов А.А. Молекулярные и
генетические механизмы формирования остеопороза у детей. Рос. педиатр. журн. 2005; 3: 37–51. / Pinelis V.G., Tikhomirov E.E., Shchepliagina L.A., Baranov A.A. Molekuliarnye i geneticheskie mekhanizmy formirovaniia osteoporoza u detei. Ros. pediatr. zhurn. 2005; 3: 37–51. [in Russian]
39. Lau KHW, Baylink DJ. Treatment of 1,25(OH)2D3(D-hormone) deficiency/resistance
with D-hormone and analogs. Osteologie 2001; 10 (1): 28–39.
40. Staal A, van Wijnen AJ, Birkenhäger JC et al. Distinct conformations of vitamin D
receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences
in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 1996; 10 (11): 1444–56.
41. Захарова И.Н., Яблочкова С.В., Дмитриева Ю.А. Известные и неизвестные эф-
фекты витамина D. Вопр. соврем. педиатрии. 2013; 12 (2): 20–5. / Zakharova I.N., Iablochkova S.V., Dmitrieva Iu.A. Izvestnye i neizvestnye effekty vitamina D. Vopr. sovrem. pediatrii. 2013; 12 (2): 20–5. [in Russian]
42. Мальцев С.В., Архипова Н.Н., Шакирова Э.М. Витамин D, кальций и фосфаты у
здоровых детей и при патологии. Казань, 2012. / Mal'tsev S.V., Arkhipova N.N., Shakirova E.M. Vitamin D, kal'tsii i fosfaty u zdorovykh detei i pri patologii. Kazan', 2012. [in Russian]
43. Шилин Д.Е. Витамин-гормон D в клинике XXI века: плейотропные эффекты и
лабораторная оценка (лекция). Клин. лаб. диагностика. 2010; 12: 17–23. / Shilin D.E. Vitamin-gormon D v klinike XXI veka: pleiotropnye effekty i laboratornaia otsenka (lektsiia). Klin. lab. diagnostika. 2010; 12: 17–23. [in Russian]
44. Christakos S, Dhawan P, Benn B et al. Vitamin D: molecular mechanism of action. Ann N Y Acad Sci 2007; 1116: 340–8.
45. Grant WB. The role of vitamin D supplements in treating health condition and diseases common among those with intellectual and/or developmental disabilities. Stand Med Pediatr 2015; 12 (5): 775–80.
46. Захарова И.Н., Дмитриева Ю.А., Васильева С.В., Евсеева Е.А. Что нужно знать
педиатру о витамине D: новые данные о его роли в организме (часть 2). Педиатрия. Журн. им. Г.Н.Сперанского. 2014; 93 (6): 125–31. / Zakharova I.N., Dmitrieva Iu.A., Vasil'eva S.V., Evseeva E.A. Chto nuzhno znat' pediatru o vitamine D:
novye dannye o ego roli v organizme (chast' 2). Pediatriia. Zhurn. im. G.N.Speranskogo.
2014; 93 (6): 125–31. [in Russian]
47. Дроздов В.Н. Дефицит витамина D как фактор полиморбидности. Эксперим.
и клин. гастроэнтерология. 2015; 118 (6): 82–8. / Drozdov V.N. Defitsit vitamina
D kak faktor polimorbidnosti. Eksperim. i klin. gastroenterologiia. 2015; 118 (6): 82–8. [in Russian]
48. Peelen E, Knippenberg S, Muris AH et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011; 10 (12): 733–43.
49. Sundaram ME, Coleman LA. Vitamin D and influenza. Adv Nutr 2012; 3 (4): 517–25.
50. Dini C, Bianchi A. The potential role of vitamin D for prevention and treatment of tuberculosis and infectious diseases. Ann Ist Super Sanita 2012; 48 (3): 319–27.
51. Bitetto D, Fabris C. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24 (1): 43–50.
52. Bergman P, Lindh БU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory
tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8 (6): e65835.
53. Herscovitch K, Dauletbaev N, Lands LC. Vitamin D as an anti-microbial and anti-inflammatory therapy for cystic fibrosis. Paediatr Respir Rev 2014; 15 (2): 154–62.
54. Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D improves inflammatory
bowel disease outcomes: basic science and clinical outcomes. World J Gastroenterol
2014; 20 (17): 4934–47.
55. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the
metabolic syndrome among U.S. adults. Diabetes Care 2005; 28 (5): 1228–30.
56. Forouhi NG, Luan J, Cooper A et al. Baseline serum 25-hydroxyvitamin d is predictive
of future glycemic status and insulin resistance: the medical research councilely prospective study 1990–2000. Diabetes 2008; 57 (10): 2619–25.
57. Каронова Т.Л., Гринева Е.Н., Михеева Е.П. и др. Уровень витамина D и его взаимосвязь с количеством жировой ткани и содержанием адипоцитокинов у женщин репродуктивного возраста. Проблемы эндокринол. 2012; 6: 19–23. / Karonova T.L., Grineva E.N., Mikheeva E.P. i dr. Uroven' vitamina D i ego vzaimosviaz' s kolichestvom zhirovoi tkani i soderzhaniem adipotsitokinov u zhenshchin reproduktivnogo vozrasta. Problemy endokrinol. 2012; 6: 19–23. [in Russian]
58. Тодиева А.М., Никитина И.Л., Каронова Т.Л. и др. Витамин D и метаболический
статус у детей и подростков с ожирением. Вопр. дет. диетологии. 2013; 11 (3): 15–22. / Todieva A.M., Nikitina I.L., Karonova T.L. i dr. Vitamin D i metabolicheskii status u detei i podrostkov s ozhireniem. Vopr. det. dietologii. 2013; 11 (3): 15–22. [in Russian]
59. Blum M, Dolnikowski G, Seyoum E, Susan SH. Vitamin D3 in fat tissue. Endocrin Rev 2008; 33: 90–4.
60. De Paula FJA, Rosen CJ. Vitamin D and fat in Vitamin D. Eds D.Feldman, J.W.Pike,
J.S.Adams. Academic Press 2011; p. 769–76.
61. Dong JY, Zhang WG, Chen JJ et al. Vitamin D intake and risk of type 1 diabetes: a
meta-analysis of observational studies. Nutrients 2013; 5 (9): 3551–62.
62. Nader NS, Aguirre Castaneda R, Wallace J et al. Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and markers of insulin resistance in obese adolescents: a prospective, randomized, placebo-controlled pilot trial. Horm Res Paediatr
2014; 82 (2): 107–12.
63. Kumar J, Muntner P, Kaskel FJ et al. Prevalence and associations of 25-Hydroxyvitamin D deficiency in US Children: NHANES 2001–2004. Pediatrics 2009; 124 (3): e362-e370.
64. Rodríguez-Rodríguez E, Ortega RM, González-Rodríguez LG, López-Sobaler AM. Vitamin D deficiency is an independent predictor of elevated triglycerides in Spanish school children. Eur J Nutr 2010; 50 (5): 373–8.
65. Li YC et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110 (2): 229–38.
66. Chowdhury R, Stevens S, Ward H et al. Circulating vitamin D, calcium and risk of
cerebrovascular disease: a systematic review and meta-analysis. Eur J Epidemiol 2012; 27 (8): 581–91.
67. Uluduz D, Adil MM, Rahim B et al. Vitamin D deficiency and osteoporosis in stroke survivors: an analysis of National Health and Nutritional Examination Survey (NHANES). J Vasc Interv Neurol 2014; 7 (1): 23–8.
68. Wang Y, Ji H, Tong Y, Zhang ZB. Prognostic value of serum 25-hydroxyvitamin D in patients with stroke. Neurochem Res 2014; 39 (7): 1332–7.
69. Whitehouse AJ, Holt BJ, Serralha M et al. Maternal serum vitamin D levels during pregnancy and offspring neurocognitive development. Pediatrics 2012; 129 (3): 485–93.
70. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008; 88 (2): 491S–9S.
71. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Archives of Bioche- mistry and Biophysics. 2012; 523 (1): 9–18.
72. Juonala M, Voipio A, Pahkala K et al. Childhood 25-OH Vitamin D Levels and Carotid
Intima-Media Thickness in Adulthood: The Cardiovascular Risk in Young Finns Study. J Clin Endocrinol Metab 2015; 100 (4): 1469–76.
73. McDonnell SL, Baggerly C, French CB et al. Serum 25Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. Plos One 2016; 11 (4).
74. Spedding S, Vanlint S, Morris H, Scragg R. Does Vitamin D Sufficiency Equate to a Single Serum 25Hydroxyvitamin D Level or Are Different Levels Required for Non- Skeletal Diseases? Nutrients 2013; 5 (12): 5127–39.
75. Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. J Steroid Biochem Mol Biol 2016.
76. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol 2016.
77. Sabetta JR, DePetrillo P, Cipriani RJ et al. Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults. Plos One 2010; 5 (6).
78. Norlin AC, Hansen S, Wahren-BorgstrЪm E et al. Vitamin D3 Supplementation and Antibiotic Consumption – Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden. PLoS One 2016; 11 (9): e0163451.
79. Priemel M, von Domarus C, Klatte TO et al. Bone Mineralization Defects and Vitamin D Deficiency: Histomorphometric Analysis of Iliac Crest Bone Biopsies and Circula- ting
25-Hydroxyvitamin D in 675 Patients. J Bone Miner Res 2010; 25 (2): 305–12.
80. Munns CF, Shaw N, Kiely M et al. Global Consensus Recommendations on Preven-
tion and Management of Nutritional Rickets. J Clin Endocrinol Metab 2016; 101 (2): 394–415.
81. Pludowski P, Karczmarewicz E, Bayer M et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe – recom- mended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Polska 2013; 64 (4): 319–27.
82. Haq A, Wimalawansa SJ, Pludowski P, Al Anouti F. Clinical practice guidelines for vitamin D in the United Arab Emirates. J Steroid Biochem Mol Biol 2016.
83. Wimalawansa SJ. Vitamin D: An essential component for skeletal health. Annals of NYAS. 2012; 1240 (1): 90–8.
84. Wimalawansa SJ. Vitamin D in the new millennium. Curr Osteoporos Rep 2012; 10 (1): 4–15.
85. Dabaj NS, Pramyothin P, Holick MF. The effect of ultraviolet radiation from a novel portable fluorescent lamp on serum 25-hydroxyvitamin D3 levels in healthy adults with Fitzpatrick skin types II and III. Photodermatol Photoimmunol Photomed 2012; 28 (6): 307–11.
86. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96 (1): 53–8.
87. Institute of Medicine (US) Comittee on Use of Dietary Reference Intakes in Nutrition
Labeling. Washington (DC): National Academies Press (US). 2003.
88. Williamson DA. Supravalvar aortic stenosis associated with mental and phy- sical retardation and characteristic facies. Proc R Soc Med 1964; 57 (2): 118–9.
89. Lightwood R, Stapleton T. Idiopathic Hypercalcaemia in Infants. Lancet 1953; 265 (AUG1): 255–6.
90. Samuel HS. Infantile Hypercalcaemia, Nutritional Rickets, and Infantile Scurvy in Great Britain. Br Med J 1964; 1 (5399): 1659–61.
91. Stapleton T, Macdonald WB, Lightwood R. The Pathogenesis of Idiopathic Hypercalcemia in Infancy. Am J Clin Nut 1957; 5 (5): 533–42.
92. Gigante M, Santangelo L, Diella S et al. Mutational Spectrum of CYP24A1 Gene in a Cohort of Italian Patients with Idiopathic Infantile Hypercalcemia. Nephron 2016; 133 (3): 193–204.
93. Schlingmann KP, Kaufmann M, Weber S et al. Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia. N Engl J Med 2011; 365 (5): 410–21.
94. Jones KL. Williams syndrome: an historical perspective of its evolution, natural history, and etiology. Am J Med Genet Suppl 1990; 6: 89–96.
95. Pober BR. Williams-Beuren Syndrome. N Engl J Med 2010; 362 (3): 239–52.
96. Holick MF. Vitamin D update 2015: What we need to know about its health benefits and potential for toxicity? Stand Med Pediatr 2015; 12 (5): 759–65.
97. Holick MF. Vitamin D Is Not as Toxic as Was Once Thought: A Historical and an Up-to-Date Perspective. Mayo Clin Proc 2015; 90 (5): 561–4.
98. Dudenkov DV, Yawn BP, Oberhelman SS et al. Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study.
Mayo Clin Proc 2015; 90 (5): 577–86.
________________________________________________
1. https://www.ncbi.nlm.nih.gov/pubmed/?term=vitamin+D on 16.10.2016.
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=vitamin+D+and+pleiotropic on 16.10.2016.
3. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014; 2 (1): 76–89.
4. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2 (4): 307–20.
5. Garland CF, Kim JJ, Mohr SB et al. Meta-analysis of AllCause Mortality According to Serum 25-Hydroxyvitamin D. Am J Public Health 2014; 104 (8): E43–E50.
6. Hossein-Nezhad A, Holick MF. Vitamin D for Health: A Global Perspective. Mayo Clin Proc 2013; 88 (7): 720–55.
7. Pludowski P, Holick MF, Pilz S et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, de- mentia and mortality – A review of recent evidence. Autoimmun Rev 2013; 12 (10): 976–89.
8. Song Y, Wang L, Pittas AG et al. Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes. Diabetes Care 2013; 36 (5): 1422–8.
9. Souberbielle JC, Body JJ, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 9 (11): 709–15.
10. Wang L, Song Y, Manson JE et al. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease A Meta-Analysis of Prospective Studies. Cir Cardiovasc Qualom 2012; 5 (6): 819–29.
11. https://www.vitamindcouncil.org/health-conditions on 16.10.2016.
12. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 2014; 72 (1): 48–54.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911–30.
14. Holick MF. Evolution and function of vitamin D. 2003.
15. Holick MF. Vitamin D: A millenium perspective. J Cell Biochem 2003.
16. Belaia Zh.E., Rozhinskaia L.Ia. Vitamin D v terapii osteoporoza: ego rol' v kombinatsii s preparatami dlia lecheniia osteoporoza, vneskeletnye effekty. Effektivnaia farmakoter. 2013 (38): 14–29. [in Russian]
17. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357; (3): 266–81.
18.Novikov P.V. Rakhit i nasledstvennye rakhitopodobnye zabolevaniia u detei. M.: Triada-Kh, 2006. [in Russian]
19. Zakharova I.N., Iablochkova S.V., Dmitrieva Iu.A. Izvestnye i neizvestnye effekty vitamina D. Vopr. sovrem. pediatrii. 2013; 12 (2): 20–5. [in Russian]
20. Zakharova I.N., Korovina N.A., Borovik T.E., Dmitrieva Iu.A. Rakhit i gipovitaminoz D – novyi vzgliad na davno sushchestvuiushchuiu problemu. Posobie dlia vrachei. M., 2011. [in Russian]
21. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin
D. Trends Biochem Sci 2004; 29 (12): 664–73.
22. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. Primer on the Metabolic Bone diseases and disorders of Mineral Metabolism ed. by M.J.Favus. 6th edition. Chapter 17. Washington, dc: American society for Bone and Mineral Research, 2006; р. 129–37.
23. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine
system essential for good health. Am J Clin Nutr 2008; 88 (2): 491–9.
24. De Borst MH, de Boer RA, Stolk RP et al. Vitamin D deficiency: universal risk factor for multifactorial diseases? Curr Drug Targets 2011; 12 (1): 97–106.
25. Ramagopalan SV, Heger A, Berlanga AJ et al. A ChIP-seq-defined genome-wide map
of vitamin D receptor binding: аssociations with disease and evolution. Genome Res 2010; 20 (10): 1352–60.
26. Torshin I.Iu., Gromova O.A. Ekspertnyi analiz dannykh v molekuliarnoi farmakologii. M.: MTsNMO, 2012. [in Russian]
27. Mikirova NA, Belcaro G, Jackson JA, Riordan NH. Vitamin D concentrations, endothelial progenitor cells, and cardiovascular risk factors. Pan Minerva Med. 2010; 52 (2 Suppl. 1): 81–7.
28. Pilz S, Tomaschitz A. Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther 2010; 8 (11): 1599–608.
29. Annweiler C, Dursun E, Feron F et al. “Vitamin D and cognition in older adults”: updated international recommendations. J Intern Med 2015; 277 (1): 45–57.
30. Mal'tsev S.V., Mansurova G.Sh. Metabolizm vitamina D i puti realizatsii ego osnovnykh funktsii. Prakticheskaia med. 2014; 9 (85): 12–8. [in Russian]
31. Hoenderop JG, Nilius B, Bindels RJ. Calcium Absorption Across Epithelia. Physiol Rev 2005; 85 (1): 373–422.
32. Hoenderop JG, van der Kemp AW, Hartog A et al. Molecular identification of the
apical Ca2+ channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J Biol Chem 1999; 274 (13): 8375–8.
33. Dardenne O, Prud’homme J, Arabian A et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142 (7): 3135–41.
34. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the vitamin D receptor exhibit
impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997; 16 (4): 391–6.
35. Ershova O.B., Belova K.Iu., Nazarova A.V. Kal'tsii i vitamin D: vse li my o nikh znaem? Rus. med. zhurn. 2011; 19 (12): 719–24. [in Russian]
36. Van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004; 10 (21): 2535–55.
37. Zotkin E.G., Shvarts G.Ia. Vozmozhnosti klinicheskogo primeneniia vitamina D i ego aktivnykh metabolitov. Effektivnaia farmakoter. 2013; 38: 50–9. [in Russian]
38. Pinelis V.G., Tikhomirov E.E., Shchepliagina L.A., Baranov A.A. Molekuliarnye i geneticheskie mekhanizmy formirovaniia osteoporoza u detei. Ros. pediatr. zhurn. 2005; 3: 37–51. [in Russian]
39. Lau KHW, Baylink DJ. Treatment of 1,25(OH)2D3(D-hormone) deficiency/resistance with D-hormone and analogs. Osteologie 2001; 10 (1): 28–39.
40. Staal A, van Wijnen AJ, Birkenhäger JC et al. Distinct conformations of vitamin D
receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences
in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 1996; 10 (11): 1444–56.
41. Zakharova I.N., Iablochkova S.V., Dmitrieva Iu.A. Izvestnye i neizvestnye effekty vitamina D. Vopr. sovrem. pediatrii. 2013; 12 (2): 20–5. [in Russian]
42. Mal'tsev S.V., Arkhipova N.N., Shakirova E.M. Vitamin D, kal'tsii i fosfaty u zdorovykh detei i pri patologii. Kazan', 2012. [in Russian]
43. Shilin D.E. Vitamin-gormon D v klinike XXI veka: pleiotropnye effekty i laboratornaia otsenka (lektsiia). Klin. lab. diagnostika. 2010; 12: 17–23. [in Russian]
44. Christakos S, Dhawan P, Benn B et al. Vitamin D: molecular mechanism of action. Ann N Y Acad Sci 2007; 1116: 340–8.
45. Grant WB. The role of vitamin D supplements in treating health condition and diseases common among those with intellectual and/or developmental disabilities. Stand Med Pediatr 2015; 12 (5): 775–80.
46. Zakharova I.N., Dmitrieva Iu.A., Vasil'eva S.V., Evseeva E.A. Chto nuzhno znat' pediatru o vitamine D: novye dannye o ego roli v organizme (chast' 2). Pediatriia. Zhurn. im. G.N.Speranskogo. 2014; 93 (6): 125–31. [in Russian]
47. Drozdov V.N. Defitsit vitamina D kak faktor polimorbidnosti. Eksperim. i klin. gastroenterologiia. 2015; 118 (6): 82–8. [in Russian]
48. Peelen E, Knippenberg S, Muris AH et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011; 10 (12): 733–43.
49. Sundaram ME, Coleman LA. Vitamin D and influenza. Adv Nutr 2012; 3 (4): 517–25.
50. Dini C, Bianchi A. The potential role of vitamin D for prevention and treatment of tuberculosis and infectious diseases. Ann Ist Super Sanita 2012; 48 (3): 319–27.
51. Bitetto D, Fabris C. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24 (1): 43–50.
52. Bergman P, Lindh БU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory
tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8 (6): e65835.
53. Herscovitch K, Dauletbaev N, Lands LC. Vitamin D as an anti-microbial and anti-inflammatory therapy for cystic fibrosis. Paediatr Respir Rev 2014; 15 (2): 154–62.
54. Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical outcomes. World J Gastroenterol 2014; 20 (17): 4934–47.
55. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the
metabolic syndrome among U.S. adults. Diabetes Care 2005; 28 (5): 1228–30.
56. Forouhi NG, Luan J, Cooper A et al. Baseline serum 25-hydroxyvitamin d is predictive of future glycemic status and insulin resistance: the medical research councilely prospective study 1990–2000. Diabetes 2008; 57 (10): 2619–25.
57. Karonova T.L., Grineva E.N., Mikheeva E.P. i dr. Uroven' vitamina D i ego vzaimosviaz' s kolichestvom zhirovoi tkani i soderzhaniem adipotsitokinov u zhenshchin reproduktivnogo vozrasta. Problemy endokrinol. 2012; 6: 19–23. [in Russian]
58. Todieva A.M., Nikitina I.L., Karonova T.L. i dr. Vitamin D i metabolicheskii status u detei i podrostkov s ozhireniem. Vopr. det. dietologii. 2013; 11 (3): 15–22. [in Russian]
59. Blum M, Dolnikowski G, Seyoum E, Susan SH. Vitamin D3 in fat tissue. Endocrin Rev 2008; 33: 90–4.
60. De Paula FJA, Rosen CJ. Vitamin D and fat in Vitamin D. Eds D.Feldman, J.W.Pike,
J.S.Adams. Academic Press 2011; p. 769–76.
61. Dong JY, Zhang WG, Chen JJ et al. Vitamin D intake and risk of type 1 diabetes: a
meta-analysis of observational studies. Nutrients 2013; 5 (9): 3551–62.
62. Nader NS, Aguirre Castaneda R, Wallace J et al. Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and markers of insulin resistance in obese adolescents: a prospective, randomized, placebo-controlled pilot trial. Horm Res Paediatr
2014; 82 (2): 107–12.
63. Kumar J, Muntner P, Kaskel FJ et al. Prevalence and associations of 25-Hydroxyvitamin D deficiency in US Children: NHANES 2001–2004. Pediatrics 2009; 124 (3): e362-e370.
64. Rodríguez-Rodríguez E, Ortega RM, González-Rodríguez LG, López-Sobaler AM. Vitamin D deficiency is an independent predictor of elevated triglycerides in Spanish school children. Eur J Nutr 2010; 50 (5): 373–8.
65. Li YC et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110 (2): 229–38.
66. Chowdhury R, Stevens S, Ward H et al. Circulating vitamin D, calcium and risk of
cerebrovascular disease: a systematic review and meta-analysis. Eur J Epidemiol 2012; 27 (8): 581–91.
67. Uluduz D, Adil MM, Rahim B et al. Vitamin D deficiency and osteoporosis in stroke survivors: an analysis of National Health and Nutritional Examination Survey (NHANES). J Vasc Interv Neurol 2014; 7 (1): 23–8.
68. Wang Y, Ji H, Tong Y, Zhang ZB. Prognostic value of serum 25-hydroxyvitamin D in patients with stroke. Neurochem Res 2014; 39 (7): 1332–7.
69. Whitehouse AJ, Holt BJ, Serralha M et al. Maternal serum vitamin D levels during pregnancy and offspring neurocognitive development. Pediatrics 2012; 129 (3): 485–93.
70. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008; 88 (2): 491S–9S.
71. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Archives of Bioche- mistry and Biophysics. 2012; 523 (1): 9–18.
72. Juonala M, Voipio A, Pahkala K et al. Childhood 25-OH Vitamin D Levels and Carotid
Intima-Media Thickness in Adulthood: The Cardiovascular Risk in Young Finns Study. J Clin Endocrinol Metab 2015; 100 (4): 1469–76.
73. McDonnell SL, Baggerly C, French CB et al. Serum 25Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. Plos One 2016; 11 (4).
74. Spedding S, Vanlint S, Morris H, Scragg R. Does Vitamin D Sufficiency Equate to a Single Serum 25Hydroxyvitamin D Level or Are Different Levels Required for Non- Skeletal Diseases? Nutrients 2013; 5 (12): 5127–39.
75. Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. J Steroid Biochem Mol Biol 2016.
76. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol 2016.
77. Sabetta JR, DePetrillo P, Cipriani RJ et al. Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults. Plos One 2010; 5 (6).
78. Norlin AC, Hansen S, Wahren-BorgstrЪm E et al. Vitamin D3 Supplementation and Antibiotic Consumption – Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden. PLoS One 2016; 11 (9): e0163451.
79. Priemel M, von Domarus C, Klatte TO et al. Bone Mineralization Defects and Vitamin D Deficiency: Histomorphometric Analysis of Iliac Crest Bone Biopsies and Circula- ting
25-Hydroxyvitamin D in 675 Patients. J Bone Miner Res 2010; 25 (2): 305–12.
80. Munns CF, Shaw N, Kiely M et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 2016; 101 (2): 394–415.
81. Pludowski P, Karczmarewicz E, Bayer M et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe – recom- mended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Polska 2013; 64 (4): 319–27.
82. Haq A, Wimalawansa SJ, Pludowski P, Al Anouti F. Clinical practice guidelines for vitamin D in the United Arab Emirates. J Steroid Biochem Mol Biol 2016.
83. Wimalawansa SJ. Vitamin D: An essential component for skeletal health. Annals of NYAS. 2012; 1240 (1): 90–8.
84. Wimalawansa SJ. Vitamin D in the new millennium. Curr Osteoporos Rep 2012; 10 (1): 4–15.
85. Dabaj NS, Pramyothin P, Holick MF. The effect of ultraviolet radiation from a novel portable fluorescent lamp on serum 25-hydroxyvitamin D3 levels in healthy adults with Fitzpatrick skin types II and III. Photodermatol Photoimmunol Photomed 2012; 28 (6): 307–11.
86. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96 (1): 53–8.
87. Institute of Medicine (US) Comittee on Use of Dietary Reference Intakes in Nutrition Labeling. Washington (DC): National Academies Press (US). 2003.
88. Williamson DA. Supravalvar aortic stenosis associated with mental and phy- sical retardation and characteristic facies. Proc R Soc Med 1964; 57 (2): 118–9.
89. Lightwood R, Stapleton T. Idiopathic Hypercalcaemia in Infants. Lancet 1953; 265 (AUG1): 255–6.
90. Samuel HS. Infantile Hypercalcaemia, Nutritional Rickets, and Infantile Scurvy in Great Britain. Br Med J 1964; 1 (5399): 1659–61.
91. Stapleton T, Macdonald WB, Lightwood R. The Pathogenesis of Idiopathic Hypercalcemia in Infancy. Am J Clin Nut 1957; 5 (5): 533–42.
92. Gigante M, Santangelo L, Diella S et al. Mutational Spectrum of CYP24A1 Gene in a Cohort of Italian Patients with Idiopathic Infantile Hypercalcemia. Nephron 2016; 133 (3): 193–204.
93. Schlingmann KP, Kaufmann M, Weber S et al. Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia. N Engl J Med 2011; 365 (5): 410–21.
94. Jones KL. Williams syndrome: an historical perspective of its evolution, natural history, and etiology. Am J Med Genet Suppl 1990; 6: 89–96.
95. Pober BR. Williams-Beuren Syndrome. N Engl J Med 2010; 362 (3): 239–52.
96. Holick MF. Vitamin D update 2015: What we need to know about its health benefits and potential for toxicity? Stand Med Pediatr 2015; 12 (5): 759–65.
97. Holick MF. Vitamin D Is Not as Toxic as Was Once Thought: A Historical and an Up-to-Date Perspective. Mayo Clin Proc 2015; 90 (5): 561–4.
98. Dudenkov DV, Yawn BP, Oberhelman SS et al. Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study.
Mayo Clin Proc 2015; 90 (5): 577–86.
Авторы
П.Плудовский1, И.Н.Захарова2, Л.Я.Климов*3
1 Детский мемориальный институт здоровья, Варшава, Польша;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
3 ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
*klimov_leo@mail.ru
________________________________________________
P.Pludowski1, I.N.Zakharova2, L.Ya.Klimov*3
1 The Children‘s Memorial Health Institute Warsaw, Masovian District, Poland;
2 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
3 Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310
*klimov_leo@mail.ru